$1.67 EPS Expected for Gilead Sciences, Inc. (GILD)

January 19, 2018 - By Darrin Black

 $1.67 EPS Expected for Gilead Sciences, Inc. (GILD)
Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported.
71,355 are owned by Inv House Ltd Liability. Keybank National Association Oh stated it has 0.26% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). 1.40M were reported by Letko Brosseau And Assoc. Cap Glob Invsts has 21.87 million shares. Ssi Inv stated it has 0.03% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Acg Wealth accumulated 2,962 shares or 0.04% of the stock. Macquarie Gru Limited holds 0.07% or 479,332 shares. Segall Bryant & Hamill Lc has invested 0.04% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Btg Pactual Global Asset Mgmt Limited invested in 8,677 shares. Choate Invest Advisors has invested 0.05% in Gilead Sciences, Inc. (NASDAQ:GILD). Of Vermont has 0.33% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Factory Mutual holds 0.52% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 588,900 shares. Credit Suisse Ag invested in 0.32% or 4.09M shares. Bank & Trust Of America Corporation De stated it has 10.39M shares. Goodwin Daniel L has invested 0.66% in Gilead Sciences, Inc. (NASDAQ:GILD).

Since August 1, 2017, it had 0 insider buys, and 12 selling transactions for $43.50 million activity. Another trade for 50,000 shares valued at $3.95 million was sold by Alton Gregg H. On Tuesday, January 2 the insider MARTIN JOHN C sold $3.68M. Another trade for 60,000 shares valued at $4.99 million was made by Meyers James R on Thursday, August 31.

Analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report $1.67 EPS on February, 6.They anticipate $0.97 EPS change or 36.74 % from last quarter’s $2.64 EPS. GILD’s profit would be $2.18 billion giving it 12.12 P/E if the $1.67 EPS is correct. After having $2.23 EPS previously, Gilead Sciences, Inc.’s analysts see -25.11 % EPS growth. The stock decreased 0.25% or $0.2 during the last trading session, reaching $80.97. About 4.29 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 19, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Market Perform” rating given on Thursday, October 5 by Leerink Swann. BMO Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, July 27 with “Hold” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Overweight” rating given on Friday, July 24 by Piper Jaffray. As per Tuesday, October 20, the company rating was maintained by Oppenheimer. As per Thursday, November 5, the company rating was upgraded by Piper Jaffray. The company was maintained on Monday, June 12 by Jefferies. The firm has “Buy” rating given on Wednesday, July 29 by Maxim Group. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 2. Maxim Group downgraded Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, April 29 to “Hold” rating. The firm earned “Overweight” rating on Wednesday, February 3 by Piper Jaffray.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $105.77 billion. The company??s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 9.22 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Fool.com which released: “2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better” on January 12, 2018, also Omaha.com with their article: “On Investments: CVS, Gilead Sciences hit the Casualty List” published on January 16, 2018, Forbes.com published: “The Intrinsic Value Of Gilead Science” on January 01, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead’s 2018 And Beyond – Buckle Up For A New Gilead” published on December 22, 2017 as well as Seekingalpha.com‘s news article titled: “2018 Is Gilead’s Year” with publication date: January 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.